On October 23, 2023, Mr. Tony Kalajian resigned from all positions in Calidi Biotherapeutics, Inc., including his roles as Chief Accounting Officer and as interim Chief Financial Officer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.242 USD | +3.60% | +4.31% | -83.97% |
16/04 | Calidi Biotherapeutics Prices $6.1 Million Offering | MT |
21/03 | H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-83.97% | 1.18Cr | |
+8.29% | 11TCr | |
+10.21% | 10TCr | |
+0.49% | 2.23TCr | |
-11.90% | 2.24TCr | |
-4.59% | 1.91TCr | |
-37.36% | 1.8TCr | |
-5.17% | 1.79TCr | |
+7.70% | 1.43TCr | |
+37.65% | 1.25TCr |
- Stock Market
- Equities
- CLDI Stock
- News Calidi Biotherapeutics, Inc.
- Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer